Lauren Flores

3PUBLICATIONS
19CO-AUTHORS
Medical molecular engineering of nucleic acids and proteinsMolecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

Sort by Publication Date:
|Feb 24, 2026
Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor.

Warren Fiskus, Christopher P Mill, Ghayas C Issa

|Nov 19, 2024
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.

Warren Fiskus, Christopher P Mill, Prithviraj Bose

|Mar 04, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.

Warren Fiskus, Jessica Piel, Mike Collins

Pageof 1

Frequent Collaborators

3 joint publications

Warren Fiskus

3 joint publications

Christopher P Mill

3 joint publications

Hanxi Hou

3 joint publications

Antrix Jain

3 joint publications

Anna Malovannaya

3 joint publications

Courtney DiNardo

3 joint publications

Sanam Loghavi

2 joint publications

Mike Collins

2 joint publications

Naval G Daver

2 joint publications

Koji Sasaki

Frequent Collaborators

3 joint publications

Warren Fiskus

3 joint publications

Christopher P Mill

3 joint publications

Hanxi Hou

3 joint publications

Antrix Jain

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us

Top Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on : Oct 17, 2025

1.0K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on : Jun 17, 2022

3.2K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on : Mar 28, 2021

2.8K
See more related videos

Top Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on : Oct 17, 2025

1.0K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on : Jun 17, 2022

3.2K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on : Mar 28, 2021

2.8K
See more related videos